Pacira BioSciences, Inc.
PCRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001396814
In the last 90 days, Pacira BioSciences, Inc. insiders filed 0 open-market purchases and 1 sale; 265 institutions reported holding it in 13F filings for Q2 2026, worth $1.40B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $70.6K in total
- 1
- 13F holdersQ2 2026, +13 vs. previous quarter
- 265
- 13F valueReported value at the end of Q2 2026
- $1.40B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding PCRX, Q2 2026
No superinvestor reported holding PCRX at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Pacira BioSciences, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 18, 2026 (view filing)5:21 PM ET | Aug 17 | 1 day | Slonin JonathanChief Medical Officer | SSale | −3.04K | $23.23 | −$70.6K | −1.4%216.4K after | 10b5-1 |
| Jun 12, 2026 (view filing) | Jun 11 | 1 day | Riker Lauren BullaroSenior Vice President, Finance | SSale | −6.12K | $23.50 | −$143.7K | −8.9%62.3K after | 10b5-1 |
| Jun 5, 2026 (view filing) | Jun 4 | 1 day | Williams Kristen MarieChief Administrative Officer | SSale | −10.3K | $22.27 | −$228.5K | −5.8%167.1K after | 10b5-1 |
| Apr 24, 2026 (view filing) | Apr 23 | 1 day | Cross ShawnChief Financial Officer | SSale | −12.9K | $25.16 | −$325.6K | −10.9%105.3K after | 10b5-1 |
| Apr 22, 2026 (view filing) | Apr 20-22 | 2 days | Cross ShawnChief Financial Officer | SSale | −12.1K | $25.09 | −$302.6K | −10.3%105.3K after | 3 lots10b5-1 |
| Mar 19, 2026 (view filing) | Mar 17 | 2 days | Slonin JonathanChief Medical Officer | SSale | −3.26K | $22.82 | −$74.4K | −1.4%223.6K after | 10b5-1 |
| Mar 19, 2026 (view filing) | Mar 17 | 2 days | Froimson MarkDirector | SSale | −500 | $21.81 | −$10.9K | −2.4%20.1K after | |
| Feb 3, 2026 (view filing) | Feb 2 | 1 day | Riker Lauren BullaroSenior Vice President, Finance | SSale | −4.00K | $20.81 | −$83.2K | −7.1%52.3K after | 10b5-1 |
| Feb 3, 2026 (view filing) | Feb 2 | 1 day | Williams Kristen MarieChief Administrative Officer | SSale | −13.1K | $20.53 | −$269.7K | −9.1%131.3K after | 10b5-1 |
| Jan 6, 2026 (view filing) | Jan 5 | 1 day | Riker Lauren BullaroSenior Vice President, Finance | SSale | −1.42K | $24.24 | −$34.3K | −2.3%59.1K after | 10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Pacira BioSciences, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 6,705,809 | $176.1M | 0.00% | −29,534−0.4% | Reduced |
| Linden Advisors LP | – | $121.9M | 0.63% | – | – |
| Context Capital Management, LLC | – | $88.7M | 1.79% | – | – |
| Doma Perpetual Capital Management LLC | 2,777,794 | $70.5M | 16.36% | 00.0% | Unchanged |
| Vanguard Portfolio Management LLC | 2,406,238 | $61.0M | 0.00% | −95,048−3.8% | Reduced |
| Dimensional Fund Advisors LP | 2,103,245 | $53.4M | 0.01% | +42,648+2.1% | Added |
| State Street Corp | 2,059,977 | $52.3M | 0.00% | +140,367+7.3% | Added |
| D. E. Shaw & Co., Inc. | 1,950,332 | $49.5M | 0.03% | −32,392−1.6% | Reduced |
| Renaissance Technologies LLC | 1,733,801 | $44.0M | 0.06% | −91,700−5.0% | Reduced |
| Vanguard Capital Management LLC | 1,691,571 | $42.9M | 0.00% | −92,478−5.2% | Reduced |